Literature DB >> 11707010

Four cases of tendinopathy in patients on statin therapy.

P Chazerain1, G Hayem, S Hamza, C Best, J M Ziza.   

Abstract

During the last decade, statins have been widely prescribed as lipid-lowering drugs. Their overall safety profile is good. The main musculoskeletal side effects have consisted of muscle pain and weakness, peripheral neuropathy, and a few cases of drug-induced lupus. We report the first four cases of tendinopathy in patients receiving statin therapy. There were three men and one woman. The diagnoses were extensortenosynovitis at the hands (case 1), tenosynovitis of the tibialis anterior tendon (case 2), and Achilles tendinopathy (cases 3 and 4). Two patients were on simvastatin and two on atorvastatin. The tendinopathy developed 1 to 2 months after treatment initiation. The outcome was consistently favorable within 1 to 2 months after discontinuation of the drug. Similar cases have been reported to French pharmacovigilance centers. This report of four cases of tendinopathy draws attention to a possible and heretofore unrecognized side effect of a drug class that is becoming increasingly popular. Statins are effective in lowering high cholesterol levels in patients with type IIa or IIb hypercholesterolemia. They have been widely used for the last decade, particularly in the secondary and primary prevention of major coronary events. Statins act by inhibiting the enzyme hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase. Although most patients tolerate statins extremely well, a few experience side effects requiring treatment discontinuation. Reported musculoskeletal side effects include myalgia and a few cases of rhabdomyolysis and polymyositis. Induced lupus and peripheral neuropathy are exceedingly rare.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11707010     DOI: 10.1016/s1297-319x(01)00300-1

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  10 in total

1.  Statin-induced calcific Achilles tendinopathy in rats: comparison of biomechanical and histopathological effects of simvastatin, atorvastatin and rosuvastatin.

Authors:  Ferda Kaleağasıoğlu; Ercan Olcay; Vakur Olgaç
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2015-08-15       Impact factor: 4.342

2.  Involvement of organic anion transporting polypeptides in the toxicity of hydrophilic pravastatin and lipophilic fluvastatin in rat skeletal myofibres.

Authors:  K Sakamoto; H Mikami; J Kimura
Journal:  Br J Pharmacol       Date:  2008-05-26       Impact factor: 8.739

3.  [Pharmacological interactions of statins].

Authors:  J M Alvarez Gutiérrez; J D López-Torres Hidalgo; P Galdón Blesa; E M García Ruiz; F Naharro de Mora
Journal:  Aten Primaria       Date:  2003-03-15       Impact factor: 1.137

4.  Atorvastatin-induced severe gastric ulceration: a case report.

Authors:  Ihab I El-Hajj; Fadi H Mourad; Nina S Shabb; Kassem A Barada
Journal:  World J Gastroenterol       Date:  2005-05-28       Impact factor: 5.742

5.  The Risk of Achilles or Biceps Tendon Rupture in New Statin Users: A Propensity Score-Matched Sequential Cohort Study.

Authors:  Julia Spoendlin; J Bradley Layton; Mallika Mundkur; Christian Meier; Susan S Jick; Christoph R Meier
Journal:  Drug Saf       Date:  2016-12       Impact factor: 5.606

Review 6.  Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism.

Authors:  Beatrice A Golomb; Marcella A Evans
Journal:  Am J Cardiovasc Drugs       Date:  2008       Impact factor: 3.571

Review 7.  Drug-induced musculoskeletal disorders.

Authors:  Bernard Bannwarth
Journal:  Drug Saf       Date:  2007       Impact factor: 5.228

8.  Ultrasound diagnosis of bilateral quadriceps tendon rupture after statin use.

Authors:  Ryan D Nesselroade; Leslie Connor Nickels
Journal:  West J Emerg Med       Date:  2010-09

9.  Achilles tendon structure is negatively correlated with body mass index, but not influenced by statin use: A cross-sectional study using ultrasound tissue characterization.

Authors:  Agnetha de Sá; David A Hart; Karim Khan; Alexander Scott
Journal:  PLoS One       Date:  2018-06-21       Impact factor: 3.240

10.  Amlamax in the management of dyslipidemia in humans.

Authors:  B Antony; B Merina; V Sheeba
Journal:  Indian J Pharm Sci       Date:  2008 Jul-Aug       Impact factor: 0.975

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.